- Showcases Allplex™ HPV products designed to test
for 14 high-risk HPV genotypes
- Advocates HPV testing for early diagnosis and prevention
of cervical cancer
- Aims to accelerate the widespread adoption of syndromic
PCR testing to create "a world free from all diseases"
SEOUL,
South Korea, July 16,
2024 /CNW/ -- Seegene Inc. (KQ096530), a
leading South Korean company providing a total solution for PCR
molecular diagnostics, demonstrated its human papillomavirus (HPV)
diagnostic products and underscored the critical importance of HPV
screening test at the Asia-Oceania Research Organization in Genital
Infection and Neoplasia (AOGIN) conference, held in Seoul, South Korea from July 11-13.
At the AOGIN, Seegene presented its advanced technologies for
identifying viruses linked to cervical cancer. The company
organized an exhibition booth and hosted a symposium session under
the theme of 'Navigating clinical guidelines and implementations
for HPV cervical cancer screening.'
The company showcased its unique quantitative PCR
technology-based HPV diagnostic products, 'Allplex™ HPV HR
Detection' and 'Allplex™ HPV28 Detection'. The Allplex™ HPV HR
Detection is designed to test for 14 high-risk HPVs, including
types 16 and 18, in a single tube. The Allplex™ HPV28 Detection is
designed to test for 28 HPVs, in two tubes, including 19 high-risk
types and 9 low-risk types, in two tubes. The products are ideal
for cervical cancer prevention and follow-up management.
The company also introduced Seegene's STARlet-AIOS™, a fully
automated molecular diagnostic testing system that streamlines the
entire PCR process from nucleic acid extraction to result analysis,
along with SG STATS, the company's premium platform of advanced
statistical analysis.
At the symposium session hosted by Seegene on July 11, Dr. Lan
Xu from the Shanghai Jiao Tong University of Public Health
in China presented a lecture on
"Clinical validation of human papillomavirus assays for cervical
cancer screening via the VALGENT framework." Dr. Shin-Wha Lee from the Asan Medical Center and
University of Ulsan in Korea showed her study on "Incorporating HPV
testing with genotypes in population-based screening programs."
"At AOGIN, we were able to showcase the excellence of Seegene's
PCR testing technology and HPV products. We expect our HPV products
to be adopted in cervical cancer screening programs in more
countries," said Daniel Shin,
Executive Vice-President and Chief Global Sales and Marketing
Officer at Seegene. "We are currently operating a campaign in the
global market to raise awareness about the benefits of syndromic
PCR testing, including simultaneous testing for HPV and sexually
transmitted infections (STIs). We believe the campaign will pave
the way for the widespread adoption of syndromic PCR testing,
helping to realize "a world free from all diseases."
Seegene's syndromic quantitative PCR technology is simultaneous
multiplex molecular diagnostic technology based on real-time PCR.
It allows for the detection of various pathogens causing similar
symptoms in a single tube, facilitating fast and accurate
diagnosis. Furthermore, analyzing the cycle threshold (Ct) value
helps determine the extent of the infection, which enhances medical
practice. Seegene is the first to globally commercialize '3
Ct' technology, which can provide the Ct value of three targets in
one channel.
Cervical cancer is the fourth most common cancer among women
worldwide, with the second-highest mortality rate. According to the
World Health Organization (WHO), approximately 600,000 women are
newly diagnosed with cervical cancer each year globally, resulting
in 340,000 deaths. In the Asia-Pacific region alone, about 270,000 women
are diagnosed annually, with over 140,000 deaths reported. The WHO
has set a target to achieve 70% cervical cancer screening coverage
by 2030, a significant increase from the current 20%. In 2020, only
33% of women had been screened for cervical cancer at least
once.
There are about 200 HPV genotypes, of which 99.8% of cervical
cancers are caused by HPV. Types 16 and 18 account for 70% of
cervical cancer, while 19 high-risk types are responsible for 90%
of all cancer cases. The progression to cancer depends on the
genotype of the HPV infection, the extent of the infection and
co-infection. Since most HPV infections do not present clear
symptoms, accurate detection is critical for the early diagnosis of
cervical cancer. Recently, many countries have been recommending
HPV testing instead of the Pap smear for cervical cancer
screening.
About Seegene
Seegene has 23 years of dedicated R&D, manufacturing, and
business experience around syndromic quantitative PCR technologies,
which was highlighted during the COVID-19 pandemic when it provided
over 340 million COVID-19 tests to more than 100 countries
worldwide. The core feature of Seegene's unique syndromic PCR
technologies is the ability to simultaneously test 14 pathogens
that cause similar symptoms in a single tube and provide
quantitative information on the infectivity profile to correlate
with the severity of illness.
About AOGIN 2024
The AOGIN, founded in 2004, comprises of 25 member countries in
Asia and Oceania. The organization
hosts international academic conferences focused on the treatment
and prevention of cervical cancer. This year's conference in
Seoul attracted over 500 experts
from 22 countries, including China, Japan,
and India, who shared the latest
research findings and clinical practices regarding HPV.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/seegene-showcases-hpv-diagnostic-kits-and-pcr-technology-at-aogin-2024-302197901.html
SOURCE Seegene Inc.